Benjamin F. Edwards & Company, Inc. Sarepta Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 6 shares of SRPT stock, worth $146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 76
92.11%
Holding current value
$146
Previous $10,000
90.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SRPT
# of Institutions
452Shares Held
82MCall Options Held
5.61MPut Options Held
4.17M-
Black Rock Inc. New York, NY10.3MShares$252 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$224 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$115 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$110 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$61.9 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $2.14B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...